Retinoblastoma Patient Clinical Database and Tissue Repository
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age0-18
SponsorChildren's Hospital Los Angeles
About this trial
Retinoblastoma (RB) is a primary eye cancer that forms in the back of the eye of infants and toddlers. Traditionally, RB is diagnosed without a biopsy; tumor can only be studied once an eye has been surgically removed.
Given this limitation, we use aqueous humor (AH), the clear fluid in the front of the eye to detect specific markers, or information, that comes from the tumor itself.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
All patients, age 0 days to 18 years, with a diagnosis unilateral or bilateral retinoblastoma (RB) seen at CHLA (Children's Hospital Los Angeles).
Disqualifiers
Patients referred for second opinions only and not treated at CHLA for any reason.
Trial population
All patients, age 0 days to 18 years, with a diagnosis unilateral or bilateral retinoblastoma (RB) treated at CHLA who have biospecimens taken for research during the course of treatment.
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
No trial groups listed
Trial outcomes
Primary outcomes
1
Correlation of Ocular Salvage (eye saved) with biomarkers
We aim to evaluate whether any identifiable molecular biomarkers (e.g. chromosomal alterations or tumor fraction) in the aqueous or blood can predict ocular salvage, or the likelihood of saving the eye with therapy
Time frame
through study completion, a minimum of 12 months after diagnosis and average of 24 months2
Identification of RB1 (RB Transcriptional Corepressor 1) gene mutations from the AH liquid biopsy
We aim to identify both somatic and germline RB1 gene mutations in the AH
Time frame
through study completion, a minimum of 12 months after diagnosis and average of 24 monthsSecondary outcomes
1
Correlation of High-Risk Histopathologic Features with presence of biomarkers
We aim to evaluate whether any identifiable molecular biomarkers in the aqueous or blood can predict the presence of high risk histopathologic features that are known to increase risk of metastatic disease
Time frame
through study completion, a minimum of 12 months after diagnosis and average of 24 months (only if the eye is enucleated)2
Correlation of class of Seeding with presence of biomarkers
We aim to evaluate whether any identifiable molecular biomarkers in the aqueous or blood are associated with the presence of type of seeding
Time frame
through study completion, a minimum of 12 months after diagnosis and average of 24 monthsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Children's Hospital Los Angeles
Lead sponsor
National Cancer Institute (NCI)
Collaborator
Source ClinicalTrials.gov